Annotation

Dasatinib is a protein kinase inhibitor whose substrates include the BCR-ABL kinase encoded by the Philadelphia chromosome. Excerpt from the dasatinib (SPRYCEL) product monograph:

SPRYCEL (dasatinib) is indicated for the treatment of adults with: Newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase...Ph+ chronic, accelerated, or blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib mesylate...Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.

For the complete product monograph text with sections containing pharmacogenetic information highlighted, see the dasatinib product monograph.

*Disclaimer: The contents of this page have not been endorsed by HCSC and are the sole responsibility of PharmGKB.